Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vunakizumab (SHR-1314) in axial spondyloarthritis
NCT03704428Phase 1Completed
- Sponsor
- Hengrui
- Start
- Apr 2018
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vunakizumab in axial spondyloarthritis (axSpA) (5 cohorts), sponsored by Hengrui. Primary endpoints: Incidence of Treatment-Emergent Adverse Events and Incidence of Injection site reaction. Started Apr 2018; status: completed.
02
Drugs
vunakizumab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT03704428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03704428.